Kura Oncology reports positive trial results for AML treatment

Kura Oncology (KURA) and Kyowa Kirin announced positive Phase 2 KOMET-001 trial results at ASCO for ziftomenib, an oral menin inhibitor, in relapsed or refractory NPM1-mutant AML patients, showing a 23% complete remission rate. The median duration of response was 3.7 months, with 63% achieving MRD-negative status, and a favorable safety profile. The FDA has granted Breakthrough Therapy Designation and accepted the New Drug Application for ziftomenib with a PDUFA target action date of November 30, 2025, driving analyst optimism despite a 72% stock decline over the past year.

Analysis

Kura Oncology (KURA) presented positive Phase 2 KOMET-001 trial results for ziftomenib in relapsed or refractory NPM1-mutant acute myeloid leukemia (AML), demonstrating a 23% complete remission (CR) plus CR with partial hematological recovery (CRh) rate. The median duration of these responses was 3.7 months, with a notable 63% of these patients achieving minimal residual disease (MRD)-negative status. Ziftomenib's safety profile from 112 patients was favorable, characterized by limited myelosuppression, only 3% discontinuation due to treatment-related adverse events, no significant QTc prolongation, and manageable differentiation syndrome. The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ziftomenib, granting it Breakthrough Therapy Designation, and has set a Prescription Drug User Fee Act (PDUFA) target action date for November 30, 2025. Financially, Kura Oncology, valued at $540 million, maintains a strong position with more cash than debt, expected to fund operations into 2027. The company reported Q1 2025 revenue of $14.1 million, a substantial increase from zero in the prior-year quarter, attributed to strategic partnerships, though earnings per share of -$0.66 slightly missed the -$0.62 forecast. Despite the stock's 72% decline over the past year, five analysts have recently revised earnings estimates upward, and firms H.C. Wainwright and Cantor Fitzgerald reaffirmed Buy and Overweight ratings, respectively. InvestingPro analysis suggests the stock is currently undervalued.

Key Decisions for Investors

• Investors should consider the significant clinical and regulatory milestones for ziftomenib, including the positive Phase 2 data and upcoming PDUFA date of November 30, 2025, as potential catalysts, especially in light of the stock's 72% decline over the past year and prevailing analyst optimism.
• Kura Oncology's strong financial position, with a cash runway into 2027 and recent revenue generation from partnerships, warrants attention as it supports operations through potential ziftomenib approval and commercial launch, mitigating some development risks.
• It may be prudent to closely monitor forthcoming details from Kura Oncology's investor event and any further clinical or regulatory updates, as these could significantly influence the investment thesis for this clinical-stage biopharmaceutical company, particularly given the high unmet need in the targeted AML patient population.